Charles River Laboratories International Inc. closed 39.25% below its 52-week high of $274.77, which the company reached on ...

Charles River Laboratories International Inc. closed 37.75% short of its 52-week high of $274.77, which the company reached on March 22nd.

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) has received an average recommendation of “Hold” ...

Bell Asset Management, an investment management company, released its Q4 2024 “Bell Global Equities Fund” investor letter. A ...

Charles Schwab Investment Management Inc. boosted its position in shares of Charles River Laboratories International, Inc.

Charles River Labs in recent years has bought a 90% controlling interest in Noveprim, a non-human primates supplier in Mauritius, for roughly $234.6 million, plus up to $72 million in deferred and ...

Charles River Laboratories is navigating a challenging biopharmaceutical demand environment with strategic cost-saving initiatives and a focus on stabilizing revenue trends. While pricing ...

Lab services company Charles River Laboratories (NYSE:CRL) reported Q4 CY2024 results exceeding the market’s revenue expectations , but sales fell by 1.1% year on year to $1.00 billion.

Redburn Atlantic upgraded Charles River (CRL) to Neutral from Sell with an $188 price target The firm says demand in the company’s Discovery ...

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) is a leading provider of preclinical and clinical laboratory services for the pharmaceutical, biotechnology ...

PORTO, Portugal & SAN FRANCISCO--(BUSINESS WIRE)--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the ...

Revenue: US$4.05b (down 1.9% from FY 2023). Net income: US$10.3m (down 98% from FY 2023). Profit margin: 0.3% (down from 12% in FY 2023). EPS: US$0.20 (down from US$9.27 in FY 2023). Revenue was ...